ArticleActa biomaterialia2014
Designing nanogel carriers for antibacterial applications.
Article in Acta biomaterialia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 75 citations in OpenAlex.
- Advances in phytochemical-derived nanotherapeutics for multimodal eradication of multidrug-resistantFrontiers in pharmacology · 2026Review
- Nano-chitosan hydrogel alleviates Candida albicans-induced health alterations in Nile tilapia (Oreochromis niloticus): antioxidant response, neuro-behaviors, hepato-renal functions, and histopathological investigation.BMC veterinary research · 2025Article
- Nanogel: A versatile drug delivery system for the treatment of various diseases and their future perspective.Drug delivery and translational research · 2025Review
- Bio-Composite Nanogels Based on Chitosan and Hyaluronic Acid for the Treatment of Lung Infections.Gels (Basel, Switzerland) · 2024Article
- Nanoparticles incorporated hydrogels for delivery of antimicrobial agents: developments and trends.RSC advances · 2024Review
- Advances in Diagnostic Approaches and Therapeutic Management in Bovine Mastitis.Veterinary sciences · 2023Review
- Food Additives Associated with Gut Microbiota Alterations in Inflammatory Bowel Disease: Friends or Enemies?Nutrients · 2022Review
- Applications of Lysozyme, an Innate Immune Defense Factor, as an Alternative Antibiotic.Antibiotics (Basel, Switzerland) · 2021Review
- Biophysical Considerations in the Rational Design and Cellular Targeting of Flexible Polymeric Nanoparticles.Advanced materials interfaces · 2021Article
- Nanogels: A novel approach in antimicrobial delivery systems and antimicrobial coatings.Bioactive materials · 2021Review
- Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.Drug delivery and translational research · 2021Review
- Protein-Based Nanohydrogels for Bioactive Delivery.Frontiers in chemistry · 2021Review
- Micro- to Nanoscale Bio-Hybrid Hydrogels Engineered by Ionizing Radiation.Biomolecules · 2020Review
- Nanoparticles for treatment of bovineDrug delivery · 2020Review
- Review
- Nanomedicines for the Delivery of Antimicrobial Peptides (AMPs).Nanomaterials (Basel, Switzerland) · 2020Review
- Nanogels as nanocarriers for drug delivery: A review.ADMET & DMPK · 2020Review
- Article
- Microbicidal Dispersions and Coatings from Hybrid Nanoparticles of Poly (Methyl Methacrylate), Poly (Diallyl Dimethyl Ammonium) Chloride, Lipids, and Surfactants.International journal of molecular sciences · 2019Article
- Stiffness can mediate balance between hydrodynamic forces and avidity to impact the targeting of flexible polymeric nanoparticles in flow.Nanoscale · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
We have developed a novel and simple synthesis route to create nanosized (∼5nm) silver nanoparticles (Ag NPs) embedded in a biocompatible nanogel (NG) comprising degradable, natural polymers, namely dextran and lysozyme. In this study, we prepared hybrid nanogels with varying lysozyme content, evaluated their potential to reduce Ag NPs in situ (using ultraviolet-visible spectroscopy, cryo-transmission electronic microscopy, thermogravimetric analysis and Fourier transform infrared spectroscopy) and determined their antibacterial properties against Escherichia coli and Staphylococcus aureus. Lysozyme was found to enhance nucleation and stabilization of Ag NPs while limiting their growth. As lysozyme concentration increased, larger nanogels with greater loading of smaller Ag NPs were obtained. The antibacterial properties of hybrid NGs were found to depend upon nanogel type and bacterial conditions. Hybrid nanogels with the largest Ag NPs showed the lowest minimum inhibition concentration. However, the greatest bacterial killing efficiency (up to 100%) occurred within 1h if the bacteria were exposed to hybrid nanogels with smaller Ag NPs while agitating the medium. These results suggest that nanogel properties as well as antibacterial activity can be tuned by varying the lysozyme content. By targeting drug delivery (e.g. ligand grafted surface), these nanogels can be used to prevent biofilm formation and control infection without the complications (i.e. overexposure) associated with classical antibiotic delivery platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.